A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys), With Ribavirin (Copegus) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment.

Trial Profile

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys), With Ribavirin (Copegus) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2014

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PROVE-1
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 24 Sep 2009 A pooled analysis of data from the PROVE 1 and PROVE 2 trials will be presented in a poster session at AASLD 2009 on Nov 3rd.
    • 30 Apr 2009 Primary endpoint results published in New England Journal of Medicine 360: 1827-1838, No. 18, 30 Apr 2009.
    • 25 Sep 2008 Results will be presented at AASLD in Oct/Nov 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top